Abstract:Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct type of primary lung cancer which is characterized by Epstein-Barr virus (EBV) infection. Only a few hundred cases have been reported since its discovery in 1987. Due to its extreme rareness, its genomic landscape remains elusive. In this study, we performed targeted ultra-deep sequencing to interrogate the genomic profile and tumor mutation burden of 10 patients with pulmonary LELC. Ten patients with advanced pulmonary LELC patients were enrolled. Tissue biopsy samples were subjected to targeted sequencing with an average sequencing depth of 1,000x, using a panel consisting of 295 cancer-related genes, spanning 2.02Mb of human genome. TMB was calculated as the ratio of number of mutations to the size of coding region of the panel, excluding copy number variations, fusions and large genomic rearrangements. We enrolled 10 patients (4 males and 6 females) with advanced pulmonary LELC and a median age of 60. Eight of them are non-smokers and 2 are smokers. Collectively, we identified 65 somatic mutations spanning 52 genes, including 33 SNVs, 3 insertions or deletions (INDELs) and 29 copy-number amplifications (CNAs). No mutation in classic NSCLC driver gene was identified, in an agreement of published data. The most frequently mutated genes were TP53, FGFR3, FGFR4, FGFR19 and CCND1, occurring in 30% (3/10) patients followed by KIT and KMT2D, occurring in 20% (2/10) patients. Interestingly, 7 patients had mutations in epigenetic regulators, such as DNA methyltransferase and chromatin remodelers. Pathway analysis also revealed an enrichment of genes participating in chromatin remodeling and organization. Next, we compared the genomic profile of pulmonary LELC with nasopharyngeal carcinoma and EBV positive gastric cancer mutation profiles obtained from TCGA, and revealed similarity with both of them. Patients in this cohort had a median TMB of 3.75/Mb (ranged from 1.25/Mb to 10/Mb), which is significantly lowered than lung adenocarcinomas. All patients had PD-L1 overexpression; 4 of them with PD-L1 expression in greater than 50% of tumor cells and the remaining 6 patients had PD-L1 expression between 5%-49% of tumor cells. In this study, we elucidated a distinct genomic landscape associated with pulmonary LELC with no classic NSCLC driver mutation but an enrichment of mutations in epigenetic regulators. The observation of high expression of PD-L1 and lack of canonical druggable driver mutation raises the potential of immunocheckpoint blockade therapy for LELC.

Lack Of Epidermal Growth Factor Receptor Gene Mutations In Exons 19 And 21 In Primary Lymphoepithelioma-Like Carcinoma Of The Lung

Detection of Rearrangement of Anaplastic Lymphoma Kinase (ALK) and Mutation of Epidermal Growth Factor Receptor (EGFR) in Primary Pulmonary Lymphoepithelioma-Like Carcinoma.

Clinicopathological Characteristics with EGFR, ALK, ROS1 Genetic Alternation and Prognostic Analysis of Primary Lymphoepithelioma-Like Carcinoma

P2.01-121 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma

Clinicopathological And Prognostic Analyses Of 86 Resected Pulmonary Lymphoepithelioma-Like Carcinomas

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Clinical observation of pulmonary lymphoepithelioma-like carcinoma

Analysis of 9 Cases of Primary Lymphoepithelioma-like Carcinoma of the Lung and Review of Literatures

Cliulcul Analysis of Primary Lymphoepithelioma-Like Carcinoma of the Lung

[Relationship Between Mutations of Epidermal Growth Factor Receptor Gene and Clinicopathologic Features of Non-Small Cell Lung Cancers].

Clinical significance of EGFR mutations in non-small cell lung cancer

Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer

Mutation of Exon19 and Exon21 of epidermal growth factor receptor and clinical factor in nonsmall cell lung cancer

Primary pulmonary lymphoepithelioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma

Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.

A Rare Subtype of Non-small Cell Lung Cancer: Report of 159 Resected Pathological Stage I–IIIA Pulmonary Lymphoepithelioma-Like Carcinoma Cases